Valuation Hangzhou Tigermed Consulting Co., Ltd

Equities

End-of-day quote Shenzhen S.E. Other stock markets 2026-03-06			5-day change	1st Jan Change
57.37 ^CNY	+1.06%		-3.81%	+1.18%

Mar. 03	Frontage Unit Acquires Research Lab Firm from Tigermed Consulting Unit	MT
Feb. 13	Beijing Trimmune Biotech Co., Ltd. announced that it has received funding from Hangzhou Tigermed Consulting Co., Ltd	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Capitalization ¹	139,718	104,196	87,567	44,807	43,882	46,790	46,790	-
Change	-	-25.42%	-15.96%	-48.83%	-2.06%	6.63%	0%	-
Enterprise Value (EV) ¹	129,700	96,434	82,021	40,354	44,261	46,337	46,234	45,920
Change	-	-25.65%	-14.95%	-50.8%	9.68%	4.69%	-0.22%	-0.68%
P/E ratio	73.8x	38.7x	45x	23.5x	116x	41.6x	36.1x	29.7x
PBR	8.75x	6.15x	4.67x	2.28x	2.28x	2.26x	2.17x	2.06x
PEG	-	0.8x	-1.5x	54.76x	-1.5x	0x	2.4x	1.4x
Capitalization / Revenue	43.8x	20x	12.4x	6.07x	6.65x	6.73x	5.94x	5.28x
EV / Revenue	40.6x	18.5x	11.6x	5.47x	6.7x	6.67x	5.87x	5.18x
EV / EBITDA	56.2x	25.2x	27.7x	13.7x	31.7x	26.1x	25.4x	19.9x
EV / EBIT	58.4x	26.1x	30.6x	15.5x	84.6x	65.6x	39.1x	30.4x
EV / FCF	154x	91.3x	90x	47.9x	59.8x	55.4x	37.6x	29.2x
FCF Yield	0.65%	1.1%	1.11%	2.09%	1.67%	1.81%	2.66%	3.42%
Dividend per Share ²	0.3	0.5	0.55	0.568	0.3	0.4503	0.4721	0.6126
Rate of return	0.19%	0.39%	0.52%	1.03%	0.55%	0.78%	0.82%	1.07%
EPS ²	2.19	3.3	2.33	2.34	0.47	1.378	1.589	1.934
Distribution rate	13.7%	15.2%	23.6%	24.3%	63.8%	32.7%	29.7%	31.7%
Net sales ¹	3,192	5,214	7,085	7,384	6,603	6,950	7,876	8,859
EBITDA ¹	2,308	3,820	2,963	2,949	1,395	1,777	1,822	2,312
EBIT ¹	2,222	3,697	2,678	2,610	523.2	706.8	1,182	1,510
Net income ¹	1,750	2,874	2,016	2,027	405.1	1,193	1,171	1,548
Net Debt ¹	-10,018	-7,762	-5,546	-4,452	378.9	-453.2	-556	-869.9
Reference price ²	161.61	127.80	104.80	54.97	54.62	57.37	57.37	57.37
Nbr of stocks (in thousands)	872,509	860,729	864,949	866,366	861,293	855,142	855,142	-
Announcement Date	3/29/21	3/10/22	3/28/23	3/28/24	3/27/25	-	-	-

¹CNY in Million²CNY

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
HANGZHOU TIGERMED CONSULTING CO., LTD	41.2x	6.56x	25.67x	0.79%	6.78B
LONZA GROUP AG	36.01x	5.23x	17.54x	0.95%	45.49B
BEONE MEDICINES AG	52.87x	4.53x	30.57x	-.--%	33.41B
CELLTRION, INC.	56.17x	11.5x	32.16x	0.34%	31.32B
IQVIA HOLDINGS INC.	21.64x	2.5x	10.76x	-.--%	29.29B
REVOLUTION MEDICINES, INC.	-13.01x	321.38x	-11.04x	-.--%	19.5B
ASCENDIS PHARMA A/S	44.81x	8.58x	30.38x	-.--%	14.77B
EUROFINS SCIENTIFIC SE	21.47x	1.97x	8.59x	1.15%	13.22B
MEDPACE HOLDINGS, INC.	27.45x	4.38x	19.93x	-.--%	13.36B
IONIS PHARMACEUTICALS, INC.	-18.59x	14.5x	-20.21x	-.--%	12.23B
Average	27.00x	38.11x	14.44x	0.32%	21.94B
Weighted average by Cap.	31.49x	34.29x	16.79x	0.34%